MOORESVILLE, N.C. – Biohaven Pharmaceuticals announced Tuesday that Nurtec ODT will be the primary sponsor on the No. 51 Ligier JS P217 entry fielded by RWR Eurasia in the LMP2 class during the Rolex 24 at Daytona Int’l Speedway on Jan. 30-31.
Austin Dillon, Cody Ware and Salih Yoluc are the three drivers confirmed to drive the No. 51 entry. A fourth driver will be announced at a later date.
“We are really excited to join the field for the 24 Hours of Daytona this year,” said team co-owner Rick Ware. “This is just another step in the storied history of this organization, and we are hoping for a great run at the end of next month.”
“Speed and endurance are two words that describe the rapid onset of action and lasting effect when patients consider treatment options for relief from their migraine attacks,” said Vlad Coric, MD, Chief Executive Officer of Biohaven. “Being a part of the 24 Hours of Daytona is another first for us as we continue to support innovative programs to drive awareness of migraine disease and the importance of acute treatment.”
Nurtec ODT was approved by the U.S. Food and Drug Administration for the acute treatment of migraine in February 2020 and is the first and only CGRP receptor antagonist available in an orally disintegrating tablet (ODT).